AIM To investigate rates of distant metastases(DM)detected with[18]fluorodeoxyglucose-positron emissiontomography/computed tomography(^(18)FDG-PET/CT)in early stage invasive breast cancer.METHODS We searched the Engli...AIM To investigate rates of distant metastases(DM)detected with[18]fluorodeoxyglucose-positron emissiontomography/computed tomography(^(18)FDG-PET/CT)in early stage invasive breast cancer.METHODS We searched the English language literature databases of PubM ed,EMBASE,ISI Web of Knowledge,Web of Science and Google Scholar,for publications on DM detected in patients who had^(18)FDG-PET/CT scans as part of the staging for early stages of breast cancer(stageⅠ?andⅡ),prior to or immediately following surgery.Reports published between 2011 and 2017 were considered.The systematic review was conducted according to the PRISMA guidelines.RESULTS Among the 18 total studies included in the analysis,the risk of DM ranged from 0%to 8.3%and 0%to 12.9%for stageⅠ?andⅡinvasive breast cancer,respectively.Among the patients with clinical stageⅡ,the rate of occult metastases diagnosed by^(18)FDG-PET/CT was 7.2%(range,0%-19.6%)for stageⅡA and 15.8%(range,0%-40.8%)for stageⅡB.In young patients(<40-yearold),^(18)FDG-PET/CT demonstrated a higher prevalence of DM at the time of diagnosis for those with aggressive histology(i.e.,triple-negative receptors and poorly differentiated grade).CONCLUSION Young patients with poorly differentiated tumors and stageⅡB triple-negative breast cancer may benefit from^(18)FDG-PET/CT at initial staging to detect occult DM prior to surgery.展开更多
文摘AIM To investigate rates of distant metastases(DM)detected with[18]fluorodeoxyglucose-positron emissiontomography/computed tomography(^(18)FDG-PET/CT)in early stage invasive breast cancer.METHODS We searched the English language literature databases of PubM ed,EMBASE,ISI Web of Knowledge,Web of Science and Google Scholar,for publications on DM detected in patients who had^(18)FDG-PET/CT scans as part of the staging for early stages of breast cancer(stageⅠ?andⅡ),prior to or immediately following surgery.Reports published between 2011 and 2017 were considered.The systematic review was conducted according to the PRISMA guidelines.RESULTS Among the 18 total studies included in the analysis,the risk of DM ranged from 0%to 8.3%and 0%to 12.9%for stageⅠ?andⅡinvasive breast cancer,respectively.Among the patients with clinical stageⅡ,the rate of occult metastases diagnosed by^(18)FDG-PET/CT was 7.2%(range,0%-19.6%)for stageⅡA and 15.8%(range,0%-40.8%)for stageⅡB.In young patients(<40-yearold),^(18)FDG-PET/CT demonstrated a higher prevalence of DM at the time of diagnosis for those with aggressive histology(i.e.,triple-negative receptors and poorly differentiated grade).CONCLUSION Young patients with poorly differentiated tumors and stageⅡB triple-negative breast cancer may benefit from^(18)FDG-PET/CT at initial staging to detect occult DM prior to surgery.
